Yunnan Botanical Pharmaceutical

Yunnan Botanical Pharmaceutical is a leading Chinese state-owned pharmaceutical company specializing in the research, development, and large-scale production of botanical-based medicines. Leveraging the diverse floral resources of Yunnan Province, the company has established a robust portfolio focused on cardiovascular and cerebrovascular health, notably through its pioneering work with Erigeron breviscapus (Dengzhanhua) and Panax notoginseng. The company operates multiple GMP-certified production lines for various dosage forms, including injections, tablets, and capsules. As a subsidiary of the Yunnan Industrial Investment Holding Group, it plays a critical role in the modernization of Traditional Chinese Medicine (TCM) and the commercialization of natural drug products for both domestic and international markets.